Selectie uit meer dan 180 peer-reviewed publicaties van ML den Boer en groepsleden:
Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: The role of kinase type and SH3 domain. Van Outersterp I, Tasian SK, Reichert CEJ, Boeree A, de Groot-Kruseman HA, Escherich G, Boer JM, Den Boer ML. Blood, 2024. PMID: 38394665 Functional study revealing that the efficacy of 3 different tyrosine kinase inhibitors depends on the type of ABL-class fusion.
Tyrosine kinase inhibitor resistance in de novo BCR::ABL1-positive BCP-ALL beyond kinase domain mutations. Van Outersterp, I., J.M. Boer, C. van de Ven, C.E.J. Reichert, A. Boeree, B. Kruisinga, H.A. de Groot-Kruseman, G. Escherich, A. Sijs-Szabo, A.W. Rijneveld, M.L. den Boer. Blood Advances, 2024. PMID: 38386975 Functional study revealing that intrinsic mechanisms of resistance to tyrosine kinase inhibitors exists in previously untreated BCR::ABL1 positive leukemia.
B-Cell Precursor Acute Lymphoblastic Leukemia elicits an Interferon-α/β response in Bone-Marrow derived Mesenchymal Stroma. Smeets MWE, Steeghs EMP, Orsel J, Stalpers F, Vermeeren MMP, Hoogkamer AQ, Veltman K, Nierkens S, van de Ven C, den Boer ML. Haematologica, 2024. PMID: 38426282. Functional study showing a specific effect of ETV6::RUNX1 positive ALL on the bone marrow microenvironment.
Improved outcome for acute lymphoblastic leukemia by prolonging therapy for IKZF1 deletion and decreasing therapy for other risk groups. R, de Groot-Kruseman HA, Fiocco M, Verwer F, Van Overveld APJ, Sonneveld E, van der Velden VHJ, Beverloo HB, Bierings M, Dors N, de Haas V, Hoogerbrugge PM, Van der Sluis IM, Tissing WJE, Veening M, Boer JM, Den Boer ML. J Clin Oncol, 2023. PMID: 37459571., Example of bridging between clinics (Pieters, 1st author) and research (Den Boer, last author).
Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study. Den Boer ML, Cario G, Moorman AV, Boer JM, de Groot-Kruseman HA, Fiocco M, Escherich G, Imamura T, Yeoh A, Sutton R, Dalla-Pozza L, Kiyokawa N, Schrappe M, Roberts KG, Mullighan CG, Hunger SP, Vora A, Attarbaschi A, Zaliova M, Elitzur S, Cazzaniga G, Biondi A, Loh ML, Pieters R; Ponte di Legno Childhood ALL Working Group. Lancet Haematol. 2021 Jan;8(1):e55-e66. PMID: 33357483. [IF 2021: 30.153] Example of bridging between clinics and research in an international setting.
Minimal Residual Disease, Long-Term Outcome, and IKZF1 Deletions in Down Syndrome Acute Lymphoblastic Leukemia in a Matched Cohort Study. Michels N, Boer JM, Enshaei A, Sutton R, Heyman M, Ebert S, Fiocco M, de Groot-Kruseman HA, van der Velden VHJ, Barbany G, Escherich G, Vora A, Trahair T, Dalla-Pozza L, Pieters R, zur Stadt U, Schmiegelow K, Moorman AV, Zwaan CM, Den Boer ML. Lancet Haematol. 2021 Oct;8(10):e700-e710. PMID: 34560013. [IF 2021 30.153] Example of bridging between clinics and research in an international setting.
RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia. Jerchel IS, Hoogkamer AQ, Ariës IM, Steeghs EMP, Boer JM, Besselink NJM, Boeree A, van de Ven C, de Groot-Kruseman HA, de Haas V, Horstmann MA, Escherich G, Zwaan CM, Cuppen E, Koudijs MJ, Pieters R, den Boer ML. 2018 32(4):931-940. PMID: 28972594. Example of oncogenomics discovery study showing a high frequency of RAS-pathway alterations in ALL.
B-cell precursor acute lymphoblastic leukemia cells use tunneling nanotubes to orchestrate their microenvironment. Polak R, de Rooij B, Pieters R, Den Boer ML. 2015 126(21): 2404-2414. PMID: 26297738. Example of functional study showing the importance of the bone marrow niche for the vitality of leukemic cells.
Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal SV, Russell LJ, Harrison CJ, Evans WE, Van der Velden VHJ, Hoogerbrugge PM, Van Leeuwen F, Escherich G, Horstmann MA, Mohammadi Khankahdani L, Rizopoulos D, De Groot-Kruseman HA, Sonneveld E, Kuiper RP*, Den Boer ML*. Blood122, 2622-2629 (2013). PMID: 19138562 Validation of unfavorable prognosis for BCR-ABL1-like ALL in 3 independent cohorts of patients.
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Den Boer ML, Van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JGCAM, Peters TCJM, Van Zutven LJCM, Beverloo HB, Van der Spek PJ, Escherich G, Horstmann MA, Janka-Schaub GE, Kamps WA, Evans WE, Pieters R. Lancet Oncol 10:125-134 (2009). PMID: 19138562 (IF: 14.5) Discovery paper leading to identification of ABL-class and new WHO category in subsequent years.
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. Holleman A, Cheok MH, Den Boer ML, Yang W, Veerman AJP, Kazemier KM, Pei P, Cheng C, Pui CH, Relling MV, Janka-Schaub GE, Pieters R and Evans WE. N Eng J Med, 351:533-542 (2004). PMID: 15295046 (IF 38.6) Discovery paper about potential causes of resistance to classical chemotherapeutic drugs.
Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. Den Boer ML, Harms DO, Pieters R, Kazemier KM, Göbel U, Körholz D, Graubner U, Haas RJ, Jorch N, Spaar HJ, Kaspers GJL, Kamps WA, Van der Does-van den Berg A, Van Wering ER, Veerman AJP and Janka-Schaub GE. Clin. Oncol. 21, 3262-3268 (2003). PMID: 12947061 (IF 2003 10.9). Seminal paper which resulted into use of these drug response profiles to risk-stratify patients.
The clinical evaluation is reported by Schramm F, Zur Stadt U, Zimmermann M, Jorch N, Pekrun A, Borkhardt A, Imschweiler T, Christiansen H, Faber J, Schmid I, Feuchtinger T, Beron G, den Boer ML, Pieters R, Horstmann MA, Janka-Schaub GE, Escherich G. Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity. Blood Adv. 2019 Nov 26;3(22):3688-3699. PMID: 31765480
